Fundz

X4 Pharmaceuticals

BOSTON, MA · Biotechnology · 111 employees

X4 Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on driving progress for people living with rare immune disorders. The company listens to those whose challenges have been long overlooked, develops solutions to their most urgent health concerns, and delivers impact through its FDA-approved medication XOLREMDI® (mavorixafor), now commercially available in

Funding history

  • Venture - Series Unknown — $85.0M — Aug 2025
  • Venture - Series Unknown — $65.0M — Jun 2023
  • Venture - Series Unknown — $55.7M — Jul 2022
  • Venture - Series Unknown — $35.0M — Sep 2018
  • Venture - Series Unknown — $25.8M — Nov 2017

Recent signals

  • Jul 01, 2026: X4 Pharmaceuticals Appoints Kelly Gold as New Director
  • Jun 30, 2026: SEC 8-K (5.02): On June 30, 2026, X4 Pharmaceuticals, Inc. appointed Kelly Gold as a Class II director of the Company, effective July 1, 2026. This marks an expansion of the board of directors from five to six members. Kelly Gold, age 49, has been the Chief Financial Officer of CAMP4 Therapeutics Corporation since April 2022 and previously served as its Chief Business Officer. Ms. Gold's experience in finance and corporate development is anticipated to strengthen the company's governance and oversight, especially in areas related to its audit processes.
  • Oct 23, 2025: SEC 8-K (1.01): On October 23, 2025, X4 Pharmaceuticals, Inc. entered into a material definitive agreement by signing an underwriting agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC as underwriters. The Company is issuing and selling 45,860,000 shares of its common stock at a public offering price of $2.90 per share. Additionally, it is providing pre-funded warrants to purchase 700,000 shares at a price of $2.899 per share, factoring in a nominal exercise price of $0.001 per share. The underwriters have a 30-day option to purchase additional shares, indicating a strategic move to raise substantial capital through this offering.
  • Aug 25, 2025: Raised $85.0M in Venture - Series Unknown
  • Feb 19, 2025: Launched X4 Pharmaceuticals Announces Exclusive Distribution Agreement for XOLREMDI® in WHIM Syndrome with taiba rare.
  • Jun 01, 2023: Raised $65.0M in Venture - Series Unknown
  • Jul 19, 2022: Raised $55.7M in Venture - Series Unknown
  • Sep 21, 2018: Raised $35.0M in Venture - Series Unknown

See plans & pricing → Track X4 Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.